The histone deacetylase inhibitor LBH589 augments anti-tumor immunity through direct effects on tumor and immune cells leading to impaired tumor progression in vivo

被引：0
|
作者：
Woods, David M. [1 ]
Woan, Karrune V. [2 ]
Wang, Hongwei [2 ]
Cheng, Fengdong [2 ]
Wang, Zi [2 ]
Vazquez, Lianet [2 ]
Perez, Patricio [2 ]
Lienlaf, Maritza [2 ]
Rock-Klotz, Jennifer [2 ]
Sahakian, Eva [2 ]
Powers, John [2 ]
Deng, Susan [2 ]
Oscar, Merino [2 ]
Atadja, Peter [3 ]
Seto, Ed [2 ]
Pinilla-Ibarz, Javier [2 ]
Weber, Jeffrey S. [2 ]
Sotomayor, Eduardo M. [2 ]
Villagra, Alejandro [2 ]
机构：
[1] Univ S Florida, Coll Med, Tampa, FL USA
[2] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
[3] Novartis Inst BioMed Res, Boston, MA USA
来源：
CANCER RESEARCH | 2012年 / 72卷
关键词：
D O I：
10.1158/1538-7445.AM2012-3554
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3554
引用
收藏
页数：1
相关论文
共 50 条
  • [1] The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity
    Woods, David M.
    Woan, Karrune
    Cheng, Fengdong
    Wang, Hongwei
    Perez-Villarroel, Patricio
    Lee, Calvin
    Lienlaf, Maritza
    Atadja, Peter
    Seto, Edward
    Weber, Jeffrey
    Sotomayor, Eduardo M.
    Villagra, Alejandro
    MELANOMA RESEARCH, 2013, 23 (05) : 341 - 348
  • [2] Histone deacetylase inhibitor, LBH589, synergizes with an immunotherapy treatment in an in vivo murine brain tumor model
    Lisiero, Dominique Naomi
    Soto, Horacio
    Fang, Shanna
    Ribas, Antoni
    Liau, Linda
    Prins, Robert
    JOURNAL OF IMMUNOLOGY, 2009, 182
  • [3] Molecular Mechanism of the Cell Death Induced by the Histone Deacetylase Pan Inhibitor LBH589 (Panobinostat) in Wilms Tumor Cells
    Tao Yan-Fang
    Li Zhi-Heng
    Xu Li-Xiao
    Fang Fang
    Lu Jun
    Li Gang
    Cao Lan
    Wang Na-Na
    Du Xiao-Juan
    Sun Li-Chao
    Zhao Wen-Li
    Xiao Pei-Fang
    Zhao He
    Su Guang-Hao
    Li Yan-Hong
    Li Yi-Ping
    Xu Yun-Yun
    Zhou Hui-Ting
    Wu Yi
    Jin Mei-Fang
    Liu Lin
    Ni Jian
    Hu Shao-Yan
    Zhu Xue-Ming
    Feng Xing
    Wang Jian
    Pan Jian
    PLOS ONE, 2015, 10 (07):
  • [4] The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo
    Sanchez, Eric
    Shen, Jing
    Steinberg, Jeffrey
    Li, Mingjie
    Wang, Cathy
    Bonavida, Benjamin
    Chen, Haiming
    Li, Zhi-Wei
    Berenson, James R.
    LEUKEMIA RESEARCH, 2011, 35 (03) : 373 - 379
  • [5] Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589
    Qian, DZ
    Kato, Y
    Shabbeer, S
    Wei, YF
    Verheul, HMW
    Salumbides, B
    Sanni, T
    Atadja, P
    Pili, R
    CLINICAL CANCER RESEARCH, 2006, 12 (02) : 634 - 642
  • [6] A phase I trial of the histone deacetylase inhibitor panobinostat (LBH589) and epirubicin in patients with solid tumor malignancies
    Munster, P. N.
    Petrou, P.
    Ryan, C. J.
    Jahan, T. M.
    DuBois, S. G.
    Rugo, H. S.
    Chan, J. K.
    Thurn, K. T.
    Reinert, A.
    Daud, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [7] The histone deacetylase inhibitor, LBH589 blocks osteoclastogenesis, enhances osteoblast activity and reduces tumor burden in bone
    Lee, Michelle
    Labrinidis, Agatha
    Liapis, Vasilios
    Hay, Shelley
    Zinonos, Irene
    Butler, Lisa
    Ponomarev, Vladimir
    Findlay, David
    Evdokiou, Andreas
    CANCER RESEARCH, 2009, 69
  • [8] A phase I trial of the histone deacetylase inhibitor panobinostat (LBH589) and epirubicin in patients with solid tumor malignancies
    Moore, A. P.
    Thomas, S.
    Ryan, C. J.
    Jahan, T. M.
    DuBois, S. G.
    Chan, J. K.
    Thurn, K. T.
    Reinhert, A.
    Daud, A.
    Munster, P. N.
    EJC SUPPLEMENTS, 2010, 8 (07): : 130 - 131
  • [9] A phase I trial of the histone deacetylase inhibitor panobinostat (LBH589) and epirubicin in patients with solid tumor malignancies.
    Moore, A. P.
    Thomas, S.
    Ryan, C. J.
    Jahan, T. M.
    DuBois, S. G.
    Chan, J. K.
    Thurn, K. T.
    Collisson, E. A.
    Reinert, A.
    Daud, A.
    Munster, P. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [10] A phase I trial of the histone deacetylase inhibitor panobinostat (LBH589) and epirubicin in patients with solid tumor malignancies.
    Moore, Amy Patricia
    Thach-Giao Truong
    Thurn, Kenneth Ted
    Thomas, Scott
    Ryan, Charles J.
    Jahan, Thierry Marie
    DuBois, Steven G.
    Chan, John K.
    Rugo, Hope S.
    Collisson, Eric Andrew
    Raha, Paromita
    Chen, Stephanie
    Reinert, Anne
    Daud, Adil
    Munster, Pamela N.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345